Jensen V, Høyer M, Sørensen F B, Keller J, Jensen O M
Centre for Bone and Soft Tissue Sarcomas, University Hospital of Aarhus, Denmark.
Histopathology. 1996 May;28(5):437-44. doi: 10.1046/j.1365-2559.1996.333377.x.
We investigated the relationship between immunohistochemical estimates of proliferative activity and expression of bcl-2 protein and mutant p53 protein in 23 cases of soft tissue sarcoma. Furthermore, the reproducibility of estimates of proliferative activity was analysed and correlations between the variables and with mitotic score were investigated. Proliferative activity was assessed by use of monoclonal antibody MIB-1 and staining for iododeoxyuridine (IdUrd), and evaluated in multiple, random, systematically sampled fields of vision. MIB-1 indices were higher than those of IdUrd but for each case the two values were positively correlated (r = 0.78). The MIB-1 index correlated positively with mitotic score (2P < 0.001) and malignancy grade (2P = 0.001). The intraobserver reproducibility of the MIB-1 and IdUrd indices were excellent (r = 0.98 and r = 0.90, respectively). p53 expression was detected in 43% and strong bcl-2 expression was present in 57% of the studied cases. Expression of p53 and bcl-2 were not significantly correlated to proliferative activity or the histological features. We conclude, that the MIB-1 index is a reliable and reproducible estimate of proliferative activity and might improve the accuracy of conventional malignancy grading of soft tissue sarcomas. Furthermore, the results indicate that neither mutant p53 protein nor bcl-2 oncogene alone are sufficient to induce increased proliferation in these sarcomas.
我们研究了23例软组织肉瘤中增殖活性的免疫组化评估与bcl-2蛋白和突变型p53蛋白表达之间的关系。此外,分析了增殖活性评估的可重复性,并研究了各变量之间以及与有丝分裂评分的相关性。通过使用单克隆抗体MIB-1和碘脱氧尿苷(IdUrd)染色来评估增殖活性,并在多个随机、系统采样的视野中进行评估。MIB-1指数高于IdUrd指数,但对于每例病例,这两个值呈正相关(r = 0.78)。MIB-1指数与有丝分裂评分(P < 0.001)和恶性程度分级(P = 0.001)呈正相关。MIB-1和IdUrd指数的观察者内可重复性极佳(分别为r = 0.98和r = 0.90)。在43%的研究病例中检测到p53表达,57%的病例中存在强bcl-2表达。p53和bcl-2的表达与增殖活性或组织学特征无显著相关性。我们得出结论,MIB-1指数是增殖活性的可靠且可重复的评估指标,可能会提高软组织肉瘤传统恶性程度分级的准确性。此外,结果表明,单独的突变型p53蛋白或bcl-2癌基因都不足以诱导这些肉瘤的增殖增加。